Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

Sponsor
Henan Cancer Hospital
Study ID
NCT03376737
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)

Study Details

The purpose of this study is to confirm the safety and efficacy of Apatinib plus Pemetrexed as the Maintenance Therapy in Advanced Lung Adenocarcinoma.

Key Dates

Start date
Oct 12, 2017
Status verified
Dec 2017
Primary completion
Jun 30, 2018
Completion
Jun 30, 2019

Study Design

Enrollment
120 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib + Pemetrexed
    Apatinib + Pemetrexed

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: up to 2 year ]

Central Contacts

Related Studies